2024西交•通全球暑假学校“药物经济与政策”夏令营招生通知
来源：西安交通大学医学院 时间：2024-12-29 12:49:18
Anita Katharina Wagner
Anita Katharina Wagner，博士，是哈佛医学院人口医学系健康政策与保险研究部和哈佛朝圣者保健研究所的副教授。她还担任Harvard Pilgrim Health Care Ethics Program的主任。Wagner博士共同指导哈佛医学院健康政策和保险研究奖学金以及癌症政策和项目评估人口医学中心(CarPE), 评估了保险和其他政策变化对药物的可得性、可及性、可负担性和使用的影响，特别是在美国、中国和其他地方的新型癌症药物。她曾担任国际和国内研究机构的首席或高级研究员，同时也是国际药物政策领域最具影响力的学者之一，作为FDA哨兵计划的药物流行病学家，Wagner博士为跟踪美国药品安全的国家系统做出了贡献。
施李正
施李正，博士，美国杜兰大学公共卫生与热带病学院全球卫生政策与管理副系主任，Regents讲座教授，2013年创立并担任杜兰大学卫生系统分析研究中心主任。中国留美经济学会会长（2014-2015）。上海医科大学药学院药学学士，协和医科大学，中国医学科学院药学硕士，南加州大学经济学硕士，南加州大学药物经济与政策博士。Value in Health副编委，Pharmacoeconomics, Diabetes Therapy, Global Health International编委。主要研究领域为卫生技术评估和卫生经济。
方宇
方宇，教授，博士生导师，哈佛医学院博士后，教育部国家级青年人才，西安交大青年拔尖人才（A类）；从事药事管理与药物经济学研究。现任西安交通大学药学院副院长;兼任中国药学会药事管理专委会副主任委员、国际药物经济学与结果研究学会中国西北分会主席等。 主编、副主编、参编教材与专著30余本，主持国际合作、国家级、省部级纵向课题30余项，发表研究论文200余篇，其中第一或通讯作者 SCI/SSCI收录118篇，包括《柳叶刀·传染病》、《柳叶刀·全球卫生》和《英国医学杂志》等。担任
Pharmacoeconomics and Policy
(P&P
)
《药物经济与政策》（英文）期刊主编。获省级成果奖2项(第一完成人)。
张昱婷
张昱婷，博士，墨尔本大学卫生经济学教授，卫生政策和医改评估专家。张教授的研究工作旨在通过研发与评估创新策略，以改善医疗保险设计，提高卫生体系绩效，促进人群健康。她的研究方向主要集中于医疗保险市场、卫生体系和卫生政策的经济评估。应用先进的计量模型和大型数据集开展定量分析，以评估卫生政策效果，分析个体选择行为。张教授的研究成果发表在《新英格兰医学杂志》等权威医学、卫生政策和经济学领域学术期刊，并被美国广播公司（ABC）新闻、《纽约时报》、《华尔街日报》等公共传媒广泛报道。
谢峰
谢峰，加拿大麦克马斯特大学医学院临床流行病学与生物统计学教授，卫生经济与政策分析中心成员，主要研究领域是利用循证医学方法分析新药和医疗器械的有效性和成本。谢教授领导或参与了100多个国际和加拿大政府和企业资助的研究项目，其中领导了由欧洲生活质量研究基金会、加拿大国立卫生研究院、加拿大联邦卫生技术评估中心和安大略省卫生部资助的数十个项目。
姚凯诗
姚凯诗，香港中文大学药学院院长助理兼教授。主要研究方向是医学经济学，决策树和马尔可夫模型算法，以及传染病。多年来，姚教授一直致力于研究医疗技术在诊断、治疗和预防方面的成本和效果，将创新的医疗实践和技术转化为具有成本效益的临床方案，并开发研究方法来模拟治疗结果。
Dennis Xuan
Dennis Xuan,新奥尔良杜兰大学公共卫生和热带医学学院卫生政策和管理系的博士。拥有北卡罗来纳大学教堂山分校吉林斯公共卫生学院的公共卫生硕士学位。 Dennis在卫生经济研究的创建和传播方面有广泛的培训、工作经验和专业知识，特别是在成本效益分析、预算影响模型和患者报告结果研究方面。他还发表了数篇同行评议的文章和国际会议摘要，涉及药物经济学、HTA和现实世界数据分析等主题。
管晓东
管晓东，副教授，北京大学药学院药事管理与临床药学系主任，北京大学医药管理国际研究中心研究员，国家药品监督管理局药品评价中心药物警戒研究与评价重点实验室学术委员。他的主要研究方向为药品公平可及与合理使用。在Nature Reviews Clinical Oncology, JAMA Internal Medicine, JAMA Network Open, Clinical Microbiology and Infection, WHO Bulletin, Cancer Communication, BMJ Global Health等期刊发表学术论文170多篇，为中国国家药物政策与合理用药提供智力支持和科学证据。
【课程安排】
主要内容：
药物经济与政策评价是推动“全球健康”战略的一项重要政策，其中包括药物政策与药品供应保障、医保创新药物准入、药物经济学与卫生技术评估、药品临床综合评价等。因此，本次夏令营聚焦药物经济学与相关政策的前沿，推动与医药卫生、经济管理、信息技术等学科的深入融合发展，分享药品价值评估、药品市场准入、模型新方法和真实世界的研究与实践。为本领域的全球大学生和科研人员提供国际交流的高端平台。
成功完成全部讲座的学生可获得由西安交通大学颁发的暑假课程证书
【举办方式】
线上和线下相结合开展系列专题讲座，全英文授课 (腾讯会议)
【时间安排】
1．报名时间：截止到2024年8月10日
2．授课时间：2024年8月2日（初定）
【申请资格】
全球药学与相关专业本科及以上学生均可申请，课程不收取任何费用
【报名方法】
拟报名此课程的同学请点击报名链接(
https://global.xjtudlc.com/）。
扫描下方二维码加微信群获取更多线上讲座链接：
【联系方式】
李京
电话：17349018028
邮箱：Jing_Li@xjtu.edu.cn
西安交通大学医学部药学院 西安交通大学药品安全与政策研究中心 国际药物经济与结果研究学会中国西北分会
2024 XJT• Global Summer School
Pharmacoeconomics and Policy Summer Camp Enrollment
（XJTISS）
【Course overview】
In recent years, pharmacoeconomic evaluation and health technology assesment have become an indispensable part of China's medical and health system reform, especially for the national basic medical insurance drug list and the national essential drug list. As an interdisciplinary discipline, pharmaceutical economics and policy aims to guide the use of limited drug resources to maximize health outcomes. It plays an important role in drug development, production, use, post-marketing monitoring, and health insurance access.
School of Pharmacy, Xi 'an Jiaotong University, Center for Drug Safety and Policy Research Center (CDSP), Xi'an Jiaotong University, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Northwest China Chapter jointly organized the 2024 XJT•Global Summer School: Pharmacoeconomics and Policy Summer Camp. We have invited nine internationally renowned professors from Harvard Medical School, Tulane University, Sun Yat-sen University, University of Melbourne, McMaster University, The Chinese University of Hong Kong, Peking University, and Xi’an Jiaotong University to form the teaching team. With a focus on pharmacoeconomics and policy, the Summer School will provide an interdisciplinary academic experience and rich international exchange experience for students from all over the world.
【Teaching Professors】
Anita Katharina Wagner
Anita Katharina Wagner is Associate Professor in the Division of Health Policy and Insurance Research at the Department of Population Medicine at Harvard Medical School and the Harvard Pilgrim Health Care Institute. She directs the organizational Ethics Program of Point32Health, the parent company of Harvard Pilgrim Health Care and Tufts Health Plan, two non-profit health insurers in the Eastern United States, and is a member of the Harvard Ethics Leaders Group. Dr. Wagner co-directs the Harvard Medical School Fellowship in Health Policy and Insurance Research and the Department of Population Medicine Center for Cancer Policy and Program Evaluation (CarPE).
Lizheng Shi
Lizheng Shi, the endowed Regents Associate Professor in Department of Globa Health Systems and Development at School of Public Health and Tropical Medicine of Tulane University. He is also jointly appointed as clinical faculty in the Departments of Internal Medicine and Psychiatry at School of Medicine of Tulane University. He was trained as an economist (M.A. in Economics 1999 PhD in pharmaceutical economics and policy 2001) through the University of Southern California. His current research interests include comparative effectiveness research, health technology assessment (cost of illness. Cost-benefit. Cost-effectiveness. Cost utility) and health care quality, access, and evaluation. He is also interested in health informatics interventions to address health systems issues regarding quality and safety of patient care.
Yu Fang
Yu Fang, is Chairman of ISPOR Northwest China Chapter. Ministry of Education national young talents, China. Vice-Dean, School of Pharmacy, Xi’an Jiaotong University. Director of Center for Drug Safety and Policy Research, Xi’an Jiaotong University. He is engaged in pharmaceutical administration and pharmacoeconomics research, and has rich experience in organizing drug policy surveys and PE/HTA analysis. Professor Fang has published more than 200 research papers, including some published in The Lancet Infectious Diseases. Editor-in-chief of Pharmacoeconomics and Policy (P&P).
Yuting Zhang
Yuting Zhang is Professor of Health Economics at the University of Melbourne, and an expert on economic evaluations of health policy and healthcare reforms. She develops and evaluates novel strategies to improve health insurance design, health system productivity, and population health. Her research focuses on economic evaluations of health insurance market, healthcare system, and health policy. Her work uses advanced economic modelling and quantitative analyses of large data sets to study the impact of health policy and the choices of individuals. Her research has been published in leading medicine, health policy, and economics journals such as the New England Journal of Medicine, and has been featured in ABC news, the New York Times, the Wall Street Journal, and on National Public Radio.
Feng Xie
Feng Xie is Professor in the Department of Clinical Epidemiology and biostatistics at McMaster University School of Medicine and a member of the Centre for Health Economics and Policy Analysis, The research field focuses on the use of evidence-based medicine methods to analyze the effectiveness and cost of new drugs and medical devices. He has led or participated in more than 100 international and Canadian government and enterprise funded research projects. Among them, he has led dozens of projects funded by the European Foundation for Quality of Life Research, the Canadian National Institutes of Health, the Canadian Federal Centre for Health Technology Assessment and the Ontario Ministry of Health.
YOU Hoi-sze, Joyce
You Hoi-sze is Assistant Dean and Professor of the School of Pharmacy at the Chinese University of Hong Kong. Her areas of expertise are medical economics, decision trees and Markov model algorithms, and infectious diseases. She has spent many years researching the cost and effectiveness of medical technologies for diagnosis, treatment, and prevention, translating innovative medical practices and technologies into cost-effective clinical protocols, and developing research methods to simulate treatment outcomes.
Dennis Xuan
Dennis Xuan is a current PhD Candidate at the Tulane University School of Public Health and Tropical Medicine at New Orleans within the department of healthcare policy and management. He also has a master’s degree in public health from the University of North Carolina Gillings School of Public Health at Chapel Hill. Dennis has extensive training, work experience, and expertise in the creation and dissemination of health economic research, particularly in cost-effectiveness analysis, budget impact models, and patient reported outcomes research. He has also published several peer-reviewed articles and international conference abstracts across topics such as Pharmacoeconomics, HTA, and real-world data analysis.
Xiaodong Guan
Xiaodong Guan is Associate Professor and Director of the Department of Pharmaceutical Management and Clinical Pharmacology, School of Pharmacy, Peking University. He is also a researcher at the International Research Center for Pharmaceutical Management of Peking University and an academic member of the Key Laboratory of Pharmacovigilance Research and Evaluation of the Drug Evaluation Center of the State Drug Administration. His research interests are equitable access and rational use of medicines. In Nature Reviews Clinical Oncology, JAMA Internal Medicine, JAMA Network Open, Clinical Microbiology and Infection, WHO Bulletin, Cancer Communication, BMJ Global Health and other journals have published more than 170 academic papers, providing intellectual support and scientific evidence for China’s national drug policy and rational drug use.
【Curriculum system】
Pharmacoeconomics and policy evaluation is an important policy to promote the “One Health” strategy in the world, including drug policy and drug supply security, access to innovative drugs for medical insurance, pharmacoeconomics and health technology assessment, and clinical comprehensive evaluation of drugs, etc. Therefore, this Summer Camp focuses on the frontier of pharmacoeconomics and related policies, which will promote the in-depth integration and development of medicine, and share the research and practice of drug value assessment, drug market access, new model methods and the real-world studies. It will provide a high level platform for international exchange for global college students and related researchers in this field.
Upon successful completion of all lectures, students can apply for a summer course Certificate of Completion issued by Xi’an Jiaotong University.
【Registration】
Please click the following link to register the program before July 19,2024.
https://global.xjtudlc.com/
Scan the QR code to join the program Wechat group for links of online lectures.
【Module】
Free Course in English
Synchronous online and offline teaching (Tencent Meeting)
【Contact Information】
Jing Li
Tel: 17349018028 Email: Jing_Li@xjtu.edu.cn
School of Pharmacy, Xi 'an Jiaotong University
Center for Drug Safety and Policy Research Center, Xi 'an Jiaotong University (CDSP)
International Society for Pharmacoeconomics and Outcomes Research, Northwest China Chapter
